Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy

Forty-two evaluable endomyocardial biopsies were obtained from 29 patients treated with epirubicin, the 4'-epimer of doxorubicin in cumulative doses ranging from 147 mg/m2 to 888 mg/m2. In this study of the Northern California Oncology Group, myofibrillar loss and sarcoplasmic vacuolization wer...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1986-07, Vol.46 (7), p.3722-3727
Main Authors: TORTI, F. M, BRISTOW, M. M, BILLINGHAM, M. E, LUM, B. L, CARTER, S. K, HOWES, A. E, ASTON, D. A, BROWN, B. W. JR, HANNIGAN, J. F. JR, MEYERS, F. J, MITCHELL, E. P
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Biopsy
Cardiomyopathies - chemically induced
Cardiomyopathies - pathology
Doxorubicin
Drug toxicity and drugs side effects treatment
Endocardium - drug effects
Endocardium - ultrastructure
Epirubicin
Female
Heart - drug effects
Heart - radiation effects
Humans
Male
Medical sciences
Microscopy, Electron
Middle Aged
Myocardium - ultrastructure
Pharmacology. Drug treatments
Toxicity: cardiovascular system
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty-two evaluable endomyocardial biopsies were obtained from 29 patients treated with epirubicin, the 4'-epimer of doxorubicin in cumulative doses ranging from 147 mg/m2 to 888 mg/m2. In this study of the Northern California Oncology Group, myofibrillar loss and sarcoplasmic vacuolization were identified and shown to be identical to those previously described for doxorubicin. However, when these biopsies were compared to 119 biopsies obtained from 98 patients treated with doxorubicin, milligram for milligram, epirubicin caused less endomyocardial injury than doxorubicin (P = 0.0013). Age, sex, type of primary malignancy, prior cardiac disease, and hypertension did not influence the degree of histologically demonstrated anthracycline injury induced by epirubicin.
ISSN:0008-5472
1538-7445